7/31/2019 4:22:24 PM
Vertex Pharmaceuticals Inc. (VRTX) Announces $500 Mln Stock Repurchase Plan
7/31/2019 4:21:37 PM
Vertex Pharmaceuticals Inc. (VRTX) Has Raised Its 2019 Revenue Estimate To $3.60 - $3.70 Bln From $3.45 - $3.55 Bln
7/31/2019 4:06:57 PM
Vertex Q2 Non-GAAP EPS $1.26 Vs $0.94 Last Year
7/22/2019 8:19:56 AM
Vertex Submits NDA For Combination Regimen Of VX-445, Tezacaftor, Ivacaftor
7/22/2019 8:06:52 AM
Vertex Submits NDA For Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor
5/15/2019 8:35:59 AM
Vertex And Kymera Therapeutics Establish Strategic Collaboration To Develop Targeted Protein Degradation Medicines
4/30/2019 8:38:46 AM
Vertex Pharma: FDA Approves KALYDECO
4/2/2019 8:10:20 AM
Vertex Appoints Charles Wagner As EVP And CFO
3/26/2019 7:38:41 AM
William Blair Lifts Vertex Pharmaceuticals Inc. (VRTX) To Outperform From Market Perform
3/6/2019 8:20:18 AM
VRTX : Tezacaftor And Ivacaftor Meets Primary Endpoint Of Improvement In Lung Function In People With Cystic Fibrosis
2/14/2019 9:09:28 AM
Vertex Reports Positive Phase 3 Study For Tezacaftor/Ivacaftor Combination In Children Aged 6-11 Years With CF
2/5/2019 4:05:57 PM
Vertex Pharma Q4 EPS $5.97 Vs. $0.39 Year Ago
1/28/2019 9:22:14 AM
Vertex: Health Canada Grants Market Authorization For KALYDECO In Children With Certain Mutations In CFTR Gene